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Abstract
Slow wave oscillations in the electroencephalogram (EEG) during sleep may reflect both sleep need and intensity, which are
implied in homeostatic regulation. Adenosine is strongly implicated in sleep homeostasis, and a single nucleotide
polymorphism in the adenosine deaminase gene (ADA G22A) has been associated with deeper and more efficient sleep. The
present study verified the association between the ADA G22A polymorphism and changes in sleep EEG spectral power (from
C3-A2, C4-A1, O1-A2, and O2-A1 derivations) in the Epidemiologic Sleep Study (EPISONO) sample from Sa˜o Paulo, Brazil.
Eight-hundred individuals were subjected to full-night polysomnography and ADA G22A genotyping. Spectral analysis of
the EEG was carried out in all individuals using fast Fourier transformation of the signals from each EEG electrode. The
genotype groups were compared in the whole sample and in a subsample of 120 individuals matched according to ADA
genotype for age, gender, body mass index, caffeine intake status, presence of sleep disturbance, and sleep-disturbing
medication. When compared with homozygous GG genotype carriers, A allele carriers showed higher delta spectral power
in Stage 1 and Stages 3+4 of sleep, and increased theta spectral power in Stages 1, 2 and REM sleep. These changes were
seen both in the whole sample and in the matched subset. The higher EEG spectral power indicates that the sleep of
individuals carrying the A allele may be more intense. Therefore, this polymorphism may be an important source of variation
in sleep homeostasis in humans, through modulation of specific components of the sleep EEG.
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Introduction
Sleep is a complex behavior that can be understood as an active
process finely regulated and influenced by genetic and environ-
mental factors [1]. The electroencephalogram (EEG) is a valuable
tool for the characterization of brain wave oscillations seen across
sleep stages. Studies have shown that individual EEG profiles in
non-rapid eye movement (NREM) and REM sleep are genetically
determined, being one of the most heritable traits in humans
identified so far [2,3,4].
Sleep is thought to be controlled by two processes: circadian and
homeostatic regulation [5]. A growing body of evidence suggests
the participation of several neuromodulators in the homeostatic
control of the sleep-wake cycle, with the adenosinergic system
playing a relevant role [6].
Adenosine is a product of adenosine triphosphate metabolism,
and is a signaling molecule described as a ‘‘sleep-promoting’’
substance. This neuromodulator is increased in the basal forebrain
during prolonged wakefulness, and is highly correlated with slow
wave activity in NREM sleep [7,8], supporting its role in
homeostatic control. The balance between adenosine production
and degradation is controlled by an extensive network of enzymes,
receptors, and transporters, which determines its intra- and extra-
cellular concentration [6]. Adenosine deaminase (ADA) is an
enzyme that irreversibly metabolizes adenosine to inosine, and
may therefore modify the need for slow wave sleep during
extended wakefulness [6,9].
A common functional variant of the ADA gene has been
described as a G to A transition (ADA G22A; rs73598374) which
leads to the substitution of asparagine for aspartic acid at the
eightieth codon of the gene [10]. It has been found that this
functional polymorphism leads to a decrease in ADA activity in
erythrocytes and lymphocytes [11], thus being a candidate variant
in the regulation of adenosine-dependent sleep homeostasis. The
ADA G22A polymorphism has been associated with higher sleep
efficiency [12], longer slow wave sleep duration, and fewer reports
of awakenings [13]. In addition, it has been suggested that its
effects on sleep architecture may be dependent on caffeine–
a powerful competitive antagonist of adenosine receptors [12].
Studies performed in relatively small samples and under strict
experimental conditions have investigated the effect of this
polymorphism on the sleep EEG. They reported increased activity
in the delta frequency range in NREM and REM sleep [13], and
in the recovery sleep after sleep deprivation [14]. The aim of the
present study was to investigate the association between the ADA
G22A polymorphism and sleep EEG spectral power in a large
epidemiological sample from Sa˜o Paulo, Brazil.
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Materials and Methods
Ethics Statement
The study protocol was approved by the Research Ethics
Committee of the Universidade Federal de Sa˜o Paulo (CEP 0593/
06) and all volunteers read and signed the informed consent form,
according to the Declaration of Helsinki. This study is registered in
ClinicalTrials.gov (Name: Epidemiology of sleep disturbances
among adult population of the Sa˜o Paulo City; Number:
NCT00596713; URL: http://www.clinicaltrials.gov/ct2/show/
NCT00596713?term=NCT00596713&rank= 1).
Studied Subjects
The initial sample consisted of 1042 participants in the Sa˜o
Paulo Epidemiologic Sleep Study (EPISONO)–a large population-
based survey from Sa˜o Paulo, Brazil. Details about the rationale,
study design, and methodology have been published [15]. Socio-
economic and demographic data, lifestyle factors, caffeine
consumption habits, and health data were collected, as well as
polysomnographic recordings and genetic data. From the initial
sample, 958 individuals were genotyped for the ADA G22A
polymorphism and for 31 ancestry informative markers to estimate
the genetic ancestry proportions of the population, as previously
described [12].
Polysomnography and Clinical Assessment
A full-night polysomnography was performed using a digital
system (EMBLAH S7000, Embla Systems, Inc., Broomfield, CO,
USA) at the sleep laboratory. Physiological variables were
monitored continuously, and recordings were scored according
to standardized criteria [16,17].
According to the International Classification of Sleep Disorders
[18], obstructive sleep apnea syndrome (OSAS) was considered
positive if individuals had an apnea-hypopnea index (AHI)
between 5 and 14.9 and presented at least one of the following
complaints: loud snoring, daytime sleepiness, fatigue, and breath-
ing interruptions during sleep. Subjects with an AHI $15 were
also considered positive, regardless of whether they had com-
plaints. Participants were classified as insomniacs (DSM-IV) using
both subjective and objective insomnia measures. Items extracted
from the questionnaires were combined as an algorithm of the
DSM-IV general criteria to define insomnia [19]. Individuals were
evaluated for restless legs syndrome (RLS) based on standard
diagnostic criteria [20,21,22].
Spectral Analysis of Sleep EEG
A specific syntax in R (version 2.10.1) was used for spectral
analysis of the sleep EEG. Waves from C3-A2, C4-A1, O1-A2,
and O2-A1 derivations were decomposed into delta (,4 Hz),
theta (4–7.9 Hz), alpha 1 (8–9.9 Hz), alpha 2 (10–12.9 Hz), beta 1
(13–17.9 Hz), beta 2 (18–29.9 Hz), and gamma ($30 Hz)
frequency bands using fast Fourier transformation, with sampling
rate of 200 Hz, using epochs of 20 s. The filter settings used were
according to standard criteria of sleep EEG data acquisition (low
frequency filter of 0.3 Hz; high frequency filter of 35 Hz; time
constant of 0.3 seconds and notch filter of 60 Hz). Artifacts were
excluded as follows: the descriptive data (mean, standard de-
viation, median, and interquartile range) from each 20 s window
were calculated, and the 5% of time windows with the highest
signal amplitude (maximum–minimum) at each sleep stage were
considered outliers and excluded from analysis. For validation of
this procedure, an experienced polysomnographist subjectively
identified and excluded artifacts in 30 polysomnographies. Results
of the visual analysis and the R syntax were compared using
a Kappa test (k=0.79; p = 0.002), showing good agreement
between the two methods.
Statistical Analysis
Z-score standardized values of the spectral power were used for
analysis due to deviations from normality. The effects of the ADA
G22A polymorphism on the spectral power at each sleep stage and
at each electrode were tested using Student’s t-tests. After
identification of frequency bands with statistically significant
changes, GG and GA+AA genotype individuals were matched
for age, gender, body mass index (BMI), European ancestry
(estimated by the genetic ancestry informative markers), presence
of sleep disturbance (OSAS, insomnia, or RLS), use of psychoac-
tive medication which potentially affects sleep structure (phy-
totherapics, antidepressants, benzodiazepines, anticonvulsants,
muscle relaxants, and zolpidem), and caffeine intake status (report
of at least one cup of caffeine-containing drinks - coffee, tea, soft
drinks or energy drinks) in the day prior to the polysomnography,
using the Genetic method of the package MatchIt, implemented in R
(version 2.14.0) [23]. This method determines the weight each
covariate is given in order to find an optimal balance for matching
and further select a subsample to be compared. A good matching
relies on a propensity score, which, for the present data, is the
covariate balance, or how much the groups to be matched have
similar joint distribution of observed covariates [24]. Independent
samples t-tests and chi-square tests were used to validate the
matching efficiency. A weighted general linear model was applied
to estimate the effect sizes (g2) and the observed power of the
comparison of the significant bandwidths between ADA G22A
genotype groups. Statistical analyses were performed using PASW
Statistics 18.0 (Chicago, IL, USA) and the significance level was set
at p = 0.05. Results are shown as mean spectral power (mV2/Hz)
6 standard deviation.
Results
Of the 958 participants genotyped for the ADA G22A poly-
morphism, sleep EEG spectral analysis data were available from
a total of 800 individuals. Of these, 450 were female (56.3%), 259
(32.4%) were positive for OSAS, 123 (15.4%) were classified as
insomniacs, 38 (4.8%) were positive for RLS, 513 (64.1%) had at
least one of the above sleep disturbances and 78 (9.8%) were
taking medication that influences sleep. The mean age was
42.13614.27 years, mean BMI was 26.5965.27 kg/m2, and ADA
A allele frequency was 4.69%. In addition, ADA G22A genotype
distributions were according do Hardy-Weinberg Equilibrium
(X2 = 0.966; p = 0.326). Due to the low frequency of AA genotype
carriers (N= 3) these individuals were grouped together with GA
genotype carriers). No associations between ADA G22A poly-
morphism and sleep disturbances were detected (p.0.05, data not
shown).
Spectral data were obtained from all derivations (C3-A2, C4-
A1, O1-A2, and O2-A1) and for all sleep stages (1, 2, 3+4, and
REM) and compared between carriers of the GG genotype (GG
genotype group) and carriers of the A allele (GA+AA genotypes
group). In the occipital O2-A1 derivation during sleep stage 1, A
allele carriers showed higher spectral power than GG allele
carriers in the delta (17.6562.57 vs. 15.0262.58, p,0.001), theta
(4.6761.11 vs. 4.3261.21, p = 0.020), and beta 1 bands
(1.0560.37 vs. 0.956.38, p= 0.045). The GA+AA group also
showed increased power in stage 2 in the theta band (5.7261.38
vs. 4.1661.12, p,0.001), in stages 3+4 in the delta band
(24.9562.71 vs. 21.0262.32, p,0.001), and in REM sleep in
the theta band (4.4061.22 vs. 4.0261.13, p= 0.007). In addition,
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they showed higher spectral power in the theta band in C3-A2
during stage 2 (5.1661.21 vs. 3.1360.79, p,0.001) and in C4-A1
during REM sleep (4.2561.11 vs. 3.7461.00, p,0.001). Table 1
summarizes the statistically significant results of the spectral
analysis and the Table S1 shows the results for all comparisons.
To confirm the aforementioned results, we conducted a more
specific analysis using a statistical algorithm to match the GG
genotype and A allele carriers for age, gender, BMI, European
ancestry, presence of sleep disturbance, use of medication that
could influence sleep, and caffeine intake status in the day prior to
the polysomnography. The algorithm determined the weight each
aforementioned variable is given, found an optimal balance for
matching based on a propensity score and selected a subsample for
analysis. Fifty-six individuals carrying the GG genotype were
matched and compared with 64 carriers of the A allele. To
validate the matching algorithm, all the variables were compared
between the genotype groups and no differences were found
(p.0.05, Table 2). Subsequently, a general linear model using the
weights calculated by the matching algorithm was applied to verify
the observed effects of the ADA polymorphism on spectral power,
and to estimate the effect sizes and observed powers for each
comparison. Differences in delta spectral power in stages 1 and
3+4 and in theta power in stages 1 and 2 for the O2-A1 derivation
remained significant. The differences found for the C3-A2 and
C4-A1 were still significant (Table 3). These results confirmed that
the ADA polymorphism influenced sleep EEG spectral power as
observed in the whole sample. As a final point, with the purpose to
visually detect changes across all sleep stages, Figure 1 shows
a comparison of the spectral power in the delta and theta ranges
between the genotype groups.
Discussion
This research is a secondary analysis of a previous study that
investigated the effect of the ADA G22A polymorphism on sleep
parameters measured by polysomnography [12]. That study
showed that individuals carrying the A allele who consumed
caffeine in the day prior to polysomnography demonstrated higher
sleep efficiency and a greater REM sleep percentage, after
correction for age, gender, and European ancestry. The present
findings complement the previous results and comprehensively
characterize the effect of the ADA G22A polymorphism on sleep
structure, in a representative population from Sa˜o Paulo.
Slow wave oscillations in the EEG during sleep may reflect the
homeostatic regulation of both sleep need and intensity. The lower
ADA activity in carriers of the A allele might be associated with
higher homeostatic load in sleep regulatory areas of the brain, and
this may be reflected in the EEG variations observed. We found
increased spectral power in A allele carriers in the delta, theta, and
beta 1 bands during NREM sleep and in the theta band during
REM sleep. A recent study showed a positive correlation between
EEG delta power and adenosine levels in the basal forebrain and
frontal cortex of rats, after different sleep deprivation periods [8].
These findings give support to the hypothesis that individuals
carrying the less active variant of ADA have lower adenosine
Table 1. Statistically significant differences regarding electroencephalogram (EEG) spectral power values between ADA G22A
genotype groups in the EPISONO epidemiological sample.
EEG spectral power ADA genotype groups
Derivation Bandwidth Sleep stage N GG N GA+AA t p
O2-A1 Delta 1 670 15.0262.58 69 17.6562.57 28.071 ,0.001
O2-A1 Theta 1 670 4.3261.21 69 4.6761.11 22.336 0.020
O2-A1 Beta1 1 670 0.9560.38 69 1.0560.37 22.011 0.045
O2-A1 Theta 2 727 4.1661.12 72 5.7261.38 29.285 ,0.001
O2-A1 Delta 3+4 713 21.0262.32 72 24.9562.71 213.486 ,0.001
O2-A1 Theta REM 722 4.0261.13 71 4.4061.22 22.727 0.007
C3-A2 Theta 2 727 3.1360.79 72 5.1661.21 213.984 ,0.001
C4-A1 Theta REM 721 3.7461.00 71 4.2561.11 24.062 ,0.001
Results are shown by EEG derivations, bandwidth and sleep stage;
Independent samples t-test with EEG spectral power Z-score transformed value;
Results are shown as mean spectral power 6 standard deviation;
Spectral power values are represented in mV2/Hz.
doi:10.1371/journal.pone.0044154.t001
Table 2. General characteristics of the subsample matched
using MatchIt.
ADA genotype groups
Variable GG (N=56)
GA+AA
(N=64) p
Age (years) 41.38614.03 41.77614.63 0.882a
Female gender 38 (58.9%) 39 (60.9%) 0.823b
Body mass index (kg/m2) 25.9864.78 25.8065.28 0.848a
Consumed caffeinec 38 (67.9%) 43 (67.2%) 0.938b
Presence of Sleep disturbanced 37 (66.1%) 42 (65.6%) 0.802b
Use of Sleep-disturbing medicatione 6 (10.7%) 7 (10.9%) 0.969b
European Ancestry (%) 79.52615.07 80.20614.69 0.802a
aIndependent sample t-test;
bChi-square test;
cReport of at least one cup of caffeine-containing drinks (coffee, tea, soft drinks
or energy drinks) in the day prior to the polysomnography;
dObstructive Sleep Apnea Syndrome, Restless Legs Syndrome or DSM-IV
Insomnia;
ePhytotherapics, antidepressants, benzodiazepines, anticonvulsants, muscle
relaxants, or zolpidem.
doi:10.1371/journal.pone.0044154.t002
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clearance and, consequently, more slow wave activity and a higher
sleep homeostatic load. In addition, we have also demonstrated
that carriers of the A allele have higher spectral power in
frequency bands other than delta, such as beta 1 in NREM sleep,
and theta in both REM and NREM sleep. Corroborating our
findings, Bachmann et al. have previously described that the
differences in the ADA G22A genotypes could be extended to theta
and alpha oscillations, and were present also in REM sleep [14].
Table 3. Weighted electroencephalogram (EEG) spectral power means between ADA G22A genotype groups in the matched
sample.
EEG spectral power ADA genotype groups
Derivation Bandwidth Sleep stage GG (N=56) GA+AA (N=64) F p g2 Obs power
O2-A1 Delta 1 15.0262.64 17.7562.56 32.873 ,0.001 21.8% 100.0%
O2-A1 Theta 1 4.1161.51 4.6361.12 1.038 0.013 5.1% 70.6%
O2-A1 Beta1 1 0.9260.37 1.0460.38 3.248 0.074 2.7% 43.2%
O2-A1 Theta 2 4.1461.06 5.6761.36 45.817 ,0.001 28.0% 100.0%
O2-A1 Delta 3+4 21.3061.80 25.0262.66 77.827 ,0.001 39.7% 100.0%
O2-A1 Theta REM 3.9761.21 4.3261.22 2.587 0.110 2.1% 35.8%
C3-A2 Theta 2 3.2260.75 5.0861.17 103.747 ,0.001 46.8% 100.0%
C4-A1 Theta REM 3.6260.94 4.1861.10 8.399 0.004 6.6% 82.0%
Estimates of the effect size (g2) and observed power are also shown;
Weighted general linear model of EEG spectral power in matched ADA genotype groups individuals;
Individuals are matched in regard to age, sex, body mass index, caffeine intake status, European ancestry, sleep disturbance (Obstructive Sleep Apnea Syndrome,
Restless Legs Syndrome or DSM-IV Insomnia) and sleep-disturbing medication (phytotherapics, antidepressants, benzodiazepines, anticonvulsants, muscle relaxants, or
zolpidem);
Results are shown as weighted mean spectral power 6 standard deviation;
Spectral power values are represented in mV2/Hz.
doi:10.1371/journal.pone.0044154.t003
Figure 1. Weighted spectral power means between the ADA G22A genotype groups (delta and theta bands) in the matched sample
for all sleep stages. Error bars: standard deviation. *p,0.05.
doi:10.1371/journal.pone.0044154.g001
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Rete´y et al. and Bachmann et al. described for the first time the
effects of the ADA G22A polymorphism on sleep structure, EEG
spectral power, and response to sleep deprivation [13,14]. Both
studies were well-designed and had rigorous experimental
protocols, including only healthy individuals that were asked to
abstain from caffeine and alcohol, and maintain a regular sleep
schedule before the experiments. The present study aimed to
replicate the findings of these two studies in an epidemiological
sample, and to test whether these associations remained significant
in a different population with a larger number of individuals,
under no experimental control. Interestingly, the effects of the
ADA G22A polymorphism on sleep EEG were similar to those
found by the controlled studies, suggesting that the findings hold
true in different experimental settings and with different sampling
approaches. However, as the number of individuals in an
epidemiological sample increases, the population tends to become
more heterogeneous in a number of socio-demographic, lifestyle,
and clinical variables. To address this issue and examine the
findings in a more homogeneous sample without disregarding the
sources of heterogeneity, we selected GG and GA+AA subjects
that were matched for several variables using a statistical
algorithm. Associations between the ADA G22A polymorphism
and changes in delta/theta power in NREM sleep, and theta
power in REM sleep, remained significant with high estimates of
effect size and observed power. These findings corroborate the
results from the whole population and previous findings from
other studies [13,14]. In this sense, it is important to note that,
although the prevalence of clinically defined sleep disturbances
(OSAS, Insomnia and RLS combined) in the present sample is
high (64.1%) and represents the real scenario of the Brazilian
population from Sa˜o Paulo, our analytic strategy using matched
individuals was able to account for the potential confounding effect
of these disorders and helped to elucidate the real influence
exerted by the genetic variant in a population level.
The changes in EEG spectral power across sleep stages give
insights about sleep architecture and homeostasis. As shown in
Figure 1 for the matched sample, the higher delta spectral power
in NREM might be specific for certain sleep stages (1 and 3+4).
Likewise, theta spectral power was higher only in REM and stage
2 NREM sleep. Bachmann et al. similarly found that slow wave
activity was high in the first NREM sleep episode and declined
subsequently [14]. Although the present results did not consider
each sleep episode independently, taken together, these two studies
agree that A allele carriers have deeper sleep and are under higher
sleep pressure.
Although we reported relevant findings that contributed to the
characterization of the link between genetic variation and sleep
homeostasis, the present study has some limitations that deserve to
be pointed out. At first, due to the relatively low frequency of ADA
G22A polymorphism we could not assess the effect of a multipli-
cative or additive genetic model on sleep EEG spectral power.
This approach would be of great interest and is encouraged to be
performed in even larger studies with sleep EEG data and ADA
G22A genotyping. In addition, since we used the Rechtschaffen &
Kales criteria we did not recorded frontal lobe data. Once delta
activity is thought to be associated to the frontal regions [25], the
effect of ADA G22A polymorphism on the frontal electrodes would
give additional evidence to the reported findings. Another
important issue is the absence of standardized waking EEG
recordings, once it might improve the relationship between ADA
G22A polymorphism and sleep homeostasis in humans. More
specific studies with high density EEG and animal models are
encouraged to assess whether the A allele would have distinct
influence on the EEG profile of different brain regions. Neverthe-
less, our findings could bring opportunity to investigate more
specific topics in the field of genetics of sleep EEG profiles.
In conclusion, the present findings suggest that the sleep of
individuals carrying the A allele is more intense, as evidenced by
higher sleep EEG spectral power in relevant frequency bands.
Through its effects on specific components of the sleep EEG, the
ADA G22A polymorphism may be considered as an important
source of variation in sleep homeostasis in humans.
Supporting Information
Table S1 Electroencephalogram spectral power for all deriva-
tions, bandwidths, and sleep stages between ADA G22A genotype
groups in the EPISONO epidemiological sample. Independent
samples t-tests were performed and the whole sample was
included.
(XLS)
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